OgoEgbuna United StatesVertex Pharmaceuticals Inc

OgoEgbuna
Institution

Day 1 - Sunday April 14, 2024

Time Session
9 a.m.
10:30 a.m.
APOL1 Targeted Therapies: Who to Test and Which Disease to Treat?
SK100
Fatiu AbiolaArogundade Chairperson NigeriaObafemi Awolowo University Teaching Hospitals Complex/ National Postgraduate Medical College of Nigeria
FernandaSales Luiz Vianna Chairperson fslvianna@gmail.comBrazilUniversidade Federal do Rio Grande do Sul
OpeyemiOlabisi Chairperson opeyemi.olabisi@duke.eduUnited StatesDuke University School of Medicine
  • Ethical Aspects of Race-based Genetic Testing
    AnaIltis Speaker iltisas@wfu.eduUnited StatesWake Forest University
  • Contribution of ApoL1 Risk Genotype to HIVAN
    SaraladeviNaicker Speaker South AfricaUniversity of the Witwatersrand
  • Contribution of APOL1 Risk Alleles to Kidney Disease in West Africa
    DwomoaAdu Speaker dwoms@blueyonder.co.ukGhanaUniversity of Ghana Medical School
  • Targeting ApoL1: A 12-Year Journey from Genetic Discovery to Phase 2 Trials
    OgoEgbuna Speaker ogo_egbuna@vrtx.comUnited StatesVertex Pharmaceuticals Inc
  • Q and A
Hall C2